Literature DB >> 6133883

Plasma somatostatin 28 increases in response to feeding in man.

K S Polonsky, S E Shoelson, H M Docherty.   

Abstract

Tissue somatostatin-like immunoreactivity (SLI) consists of a number of molecular species including the cyclic tetradecapeptide or SRIF, an N-terminally extended form of SRIF termed somatostatin-28, as well as larger precursor peptides. The function and nature of circulating SLI is not well understood. In this report, we describe techniques for the definition of the components of plasma SLI in normal human plasma. Plasma SLI measured after gel filtration on Bio-gel P-6 columns was found to consist of from 1-3 peaks. The void volume peak was present in greatest concentration (34.2 +/- 8.9 pg/ml) and did not increase in response to a mixed meal. Very low levels of two additional peaks of SLI activity were found. To further characterize these peaks, 10-ml plasma samples were extracted and concentrated on octadecylsilyl silica (C-18) cartridges with subsequent fractionation on Bio-gel P-6 columns. The two peaks that coeluted with synthetic SRIF and S-28 markers, respectively, were present in concentrations of 5.4 +/- 1.4 and 4.8 +/- 1.9 pg/ml in fasting plasma. In response to a mixed meal, the SLI14 peak doubled (12.9 +/- 2.4 pg/ml) while the SLI28 peak increased to 29.9 +/- 7.2 pg/ml at 120 min. These results provide evidence that S-28 circulates in human plasma and its increase after feeding is consistent with a possible biological role for this peptide.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6133883      PMCID: PMC437018          DOI: 10.1172/jci110907

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  High biological activity of the synthetic replicates of somatostatin-28 and somatostatin-25.

Authors:  P Brazeau; N Ling; F Esch; P Böhlen; R Benoit; R Guillemin
Journal:  Regul Pept       Date:  1981-01

2.  Receptor binding of somatostatin-28 is tissue specific.

Authors:  C B Srikant; Y C Patel
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

3.  Radioimmunoassay of human plasma somatostatin.

Authors:  K Mackes; M Itoh; K Greene; J Gerich
Journal:  Diabetes       Date:  1981-09       Impact factor: 9.461

4.  Evidence for the hormonal status of somatostatin in man.

Authors:  E S Zyznar; A O Pietri; V Harris; R H Unger
Journal:  Diabetes       Date:  1981-10       Impact factor: 9.461

5.  Multiple forms of immunoreactive somatostatin: comparison of distribution in neural and nonneural tissues and portal plasma of the rat.

Authors:  Y C Patel; T Wheatley; C Ning
Journal:  Endocrinology       Date:  1981-12       Impact factor: 4.736

6.  Isolation of a porcine intestinal peptide with C-terminal somatostatin.

Authors:  L Pradayrol; J A Chayvialle; M Carlquist; V Mutt
Journal:  Biochem Biophys Res Commun       Date:  1978-11-29       Impact factor: 3.575

7.  Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat.

Authors:  Y C Patel; S Reichlin
Journal:  Endocrinology       Date:  1978-02       Impact factor: 4.736

8.  Measurements of somatostatin-like immunoreactivity in plasma.

Authors:  V Harris; J M Conlon; C B Srikant; K McCorkle; V Schusdziarra; E Ipp; R H Unger
Journal:  Clin Chim Acta       Date:  1978-07-15       Impact factor: 3.786

9.  A radioimmunoabsorbent assay for plasma somatostatin.

Authors:  G Lundqvist; S Gustavsson; R Elde; A Arimura
Journal:  Clin Chim Acta       Date:  1980-02-28       Impact factor: 3.786

10.  Peripheral plasma somatostatin-like immunoreactive responses to insulin hypoglycemia and a mixed meal in healthy subjects and in noninsulin-dependent maturity-onset diabetics.

Authors:  A I Vinik; N S Levitt; B L Pimstone; L Wagner
Journal:  J Clin Endocrinol Metab       Date:  1981-02       Impact factor: 5.958

View more
  11 in total

1.  Basal plasma somatostatin in biliary stone patients.

Authors:  P O Schwille; E Hanisch; W Engelhardt; D Scholz
Journal:  Klin Wochenschr       Date:  1984-06-15

Review 2.  Endogenous somatostatin and the gut.

Authors:  M R Lucey
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

3.  A physiologic role for somatostatin 28 as a regulator of insulin secretion.

Authors:  D A D'Alessio; C Sieber; C Beglinger; J W Ensinck
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

4.  Circulating prosomatostatin-derived peptides. Differential responses to food ingestion.

Authors:  J W Ensinck; E C Laschansky; R E Vogel; D A Simonowitz; B A Roos; B H Francis
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

5.  Is somatostatin a humoral regulator of the endocrine pancreas and gastric acid secretion in man?

Authors:  F B Loud; J J Holst; E Egense; B Petersen; J Christiansen
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

6.  Role of circulating somatostatin in regulation of gastric acid secretion, gastrin release, and islet cell function. Studies in healthy subjects and duodenal ulcer patients.

Authors:  T J Colturi; R H Unger; M Feldman
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

7.  Circulating somatostatin. Physiological regulator of pancreatic function?

Authors:  K Gyr; C Beglinger; E Köhler; U Trautzl; U Keller; S R Bloom
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

Review 8.  Leveraging the Gut to Treat Metabolic Disease.

Authors:  Ruth E Gimeno; Daniel A Briere; Randy J Seeley
Journal:  Cell Metab       Date:  2020-03-17       Impact factor: 27.287

9.  Selective binding of somatostatin-14 and somatostatin-28 to islet cells revealed by quantitative electron microscopic autoradiography.

Authors:  M Amherdt; Y C Patel; L Orci
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

10.  Plasma somatostatin-like immunoreactivity and somatostatin-28 levels in obese men.

Authors:  M Peracchi; F Carola; F Cavagnini; R Benti; B Bareggi; G Baccalaro; G Basilisco
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.